Could GI Parasites and Bacterial Infections Be Connected?

Harboring gastrointestinal parasites may increase a person’s risk of developing a C. diff infection, per new ...

AUGUST 6, 2025

Microbiota-Based Therapy for the Prevention of Recurrent Clostridioides difficile Infection:
A Primer on REBYOTA^®
(fecal microbiota, live-jslm)

This Special Report outlines the challenges of treating Clostridioides difficile infection (CDI) and preventing ...

AUGUST 29, 2023

Phase 3 Data Show Rebyota Safe, Effective in Reducing Recurrent CDI

The FDA approved the microbiota-based live biotherapeutic RBX2660 (Rebyota, Ferring) to prevent recurrent ...

DECEMBER 10, 2022

FDA Approves Rebyota, the First Live Biotherapeutic Fecal Microbiota Product in the U.S.

RBX2660 (Rebyota, Ferring) is approved by the FDA for the prevention of recurrent Clostridioides difficile ...

DECEMBER 2, 2022

Novel Biotherapeutic Safe, Efficacious in Treating Recurrent CDI

RBX2660, a novel microbiota-based live biotherapeutic, consistently reduced rCDI among patients who are 65 years of ...

NOVEMBER 1, 2022

Limited Access to C. diff Drugs Through Medicare

While drugs recommended for the treatment of CDI are commonly included on the formularies for most people who are ...

AUGUST 19, 2022

C. difficile Common in Brazilian ICUs, but Not Linked to Diarrhea or Mortality

Brazilian researchers at two tertiary care hospitals found 17% of a group of 92 adult ICU patients were colonized ...

MAY 16, 2022

Are Shoes a Vector for C. difficile Infections?

Strongly consider washing your hands next time you tie your shoelaces. According to an international study of ...

OCTOBER 21, 2021

Microbiome-Based Therapy: The Next Frontier in the Management of Clostridioides difficile Infections and Recurrence

This Special Report describes the gut microbiome, the burden of Clostridioides difficile infection (CDI) and ...

JANUARY 12, 2021